Clinical Study

Treatment Outcomes and Prognostic Factors in Mexican Patients with Endometrial Carcinoma with Emphasis on Patients Receiving Radiotherapy after Surgery: An Institutional Perspective

Christian Flores, Carlos Mariscal, Alfredo Celis, Nidia M. Balcázar, Abelardo Meneses, Alejandro Mohar, Aida Mota, and Elizabeth Trejo

Department of Radiation Oncology, National Cancer Institute, St. Fernando’s Avenue 22, Tlalpan, Mexico City, Mexico

Correspondence should be addressed to Christian Flores, chrishaydee@hotmail.com

Received 15 January 2012; Accepted 4 March 2012

Academic Editors: M. Al-Sarraf and K. Sonoda

Copyright © 2012 Christian Flores et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aim. To analyze the clinical characteristics and treatment outcomes in patients with endometrial carcinoma treated in a Latin American institute with emphasis in patients receiving adjuvant radiotherapy.

Methods. A total of 412 patients with endometrial carcinoma admitted to our hospital between 1998 and 2008 were evaluated, retrospectively. The mean age was 55 years (28–87). Two hundred seventy patients received RT following surgery. Stage distribution was as follows: 221 patients (54%) stage I, 86 patients (21%) stage II, and 103 patients (24.5%) stage III and 2 patients (0.5%) stage IV A.

Results. Overall survival rate was 95% at 2 years, 84% at 5 years, and 79% at 10 years. By the end of followup, 338 patients (82%) were disease-free, and 13 (3%) were alive with disease. Univariate and multivariate analyses identified age, grade, serosal and adnexial involvement as significant predictors for overall survival.

Conclusion. The results of our study suggests that early-stage, low-grade endometrial cancer with no risk factors should not receive external beam radiotherapy, intermediate risk patients should receive only vaginal vault brachytherapy, and the use of chemotherapy with radiotherapy for patients high-risk and advanced-stage carcinoma the addition of radiotherapy is associated with a better survival being an effective therapeutic option.

1. Introduction

Endometrial carcinoma is one of the most common gynecologic malignancies in Mexican women after uterine cervix, ovarian and breast cancers [1]. In our country, cancer has had an important rise in the last 50 years. According to the last data from National Tumor Registry in year 2003, a total of 71,901 new cancer cases in women were registered, from these cases, 1552 belonged to uterine corpus carcinoma [2]. During years 2000–2004 in our hospital 19,264 new cases were reported with 64.6% (12,444) belonged to women. Specifically uterine corpus carcinoma ranked the fifth place for gynecologic tumors being endometrioid adenocarcinoma the most prevalent histology [3].

Fortunately, 70% of endometrial cancer patients are diagnosed with localized disease, resulting in a 5-year survival of 95% in this subset of patients [4, 5]. The median age at diagnosis is 62 years [6]. Risk factors for development of this disease include obesity, diabetes, hypertension, endogenous or exogenous estrogen, nulliparity, menopause, family history, and endometrial hyperplasia. In addition, with better surgical techniques, advances in radiotherapy and chemotherapy, the mortality rate for endometrial cancer continues to decline.

In Mexico, most endometrial cancers are surgically staged according to criteria established by the International Federation of Obstetrics and Gynecology (FIGO), this includes an hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), and pelvic/para-aortic lymph node dissection (LND), with pelvic washings and an omental biopsy [7, 8]. Management and adjuvant treatment after surgery depends upon a patient’s risk factor for recurrence, options include vaginal...
vault brachytherapy (VBT), pelvic external-beam radiation therapy (EBRT), and/or chemotherapy (CT). The most significant risk factor considered in any decision for adjuvant therapy include age, grade, histologic type, deep of myome-trial invasion, tumor extension, tumor extension beyond the uterus, and lymphovascular space invasion. Depending of these risk factors, patients are grouped into low, intermediate or high risk for recurrence. Most controversy and debate is associated with the patients stratified to the intermediate-risk group.

In this study, we analyzed the clinical characteristics and treatment outcomes in patients with endometrial cancer who received adjuvant radiotherapy after surgery. Although FIGO announced an update for endometrial cancer staging in October 2009 [9], all the cases reviewed in this study were staged according to FIGO 1988.

2. Material and Methods

A total of 869 women were admitted at the National Cancer Institute in Mexico City between January 1998 and December 2008. Inclusion criteria included Mexican nationality, >18 years old at diagnosis, stages I to IVA and histologies: endometrioid, papillary cell, clear cell, and adenosquamous. Patients were excluded if they received EBRT previously or were diagnosed with metastatic disease, uterine sarcoma, not operated and treated with EBRT only, and the presence of another synchronic tumor (i.e., breast and endometrial carcinoma) with the exception of nonmelanoma skin cancer. Four Hundred and twelve women met the inclusion criteria and were evaluated retrospectively with regard to patient characteristics and treatment outcomes. All patients were assessed at the time of diagnosis with physical examination, routine blood counts and biochemical profile, chest X Rays, and pelvic tomography was performed in some women. All patients included in this study had negative pelvic or para aortic nodes on imaging. After systematic evaluation, 120 patients were treated with TAH-BSO, 20 patients with TAH-BSO-pelvic LND, and 271 patients with TAH-BSO-pelvic/para aortic LND and omentum biopsy. Histopathological and immunohistochemical assessments were performed in all cases. The staging was based on FIGO 1988 surgical staging system. A total of 270 women received adjuvant radiotherapy, EBRT alone was administered to 11 patients, 8 patients were administered total abdominal and pelvic EBRT plus VBT, 241 patients received EBRT + VBT, 7 patients were administered only VBT, and 7 patients received EBRT to retropertioneum and pelvis besides VBT. External beam radiotherapy was given with cobalt units and 6 MV and 15 MV linear accelerators. A computed tomography scan with 5 mm cut was performed for all patients from the top of L4 to the bottom of lesser trochanters of the femurs as part of virtual simulation. Pelvic RT was administered with 4-field box method with a daily dose of 2 Gy to achieve a total dose of 50 Gy, in all cases, two-thirds of dose were administered through anterior and posterior fields, and one-third of the dose was administered through opposed lateral fields. For anterior and posterior fields (AP/PA) the upper limit was at the top of L5, lower field limit was at the bottom of the obturator foramina to cover vaginal cuff, lateral field limits were 2 cm beyond the bony margins of the pelvic inlet. Lateral opposed fields limits were the same as AP/PA fields in superior/inferior borders but in front of the pubis symphysis in anterior border and at S2-S3 level in posterior border. In patients whose para-aortic nodes were positive after surgery (Stage III), additional para aortic RT was administered at a total dose of 45 Gy with 1.8 Gy fractions, and patients with total abdominal radiotherapy were administered a total dose of 30 Gy en 1.5 Gy fractions trying to protect both kidneys and liver. Most patients received low-dose rate brachytherapy with 2, 3, and 3.5 cm cylinder applicator covering all vaginal length with a prescribed mean dose of 35 Gy at 0.5 cm depth. Doses for vagina, urinary bladder, and rectum were calculated in all patients to be under 80% of the defined doses. Side effects at vagina, urinary bladder, and rectum were classified according to the acute and late toxicity criteria as defined by the Radiation Therapy Oncology Group (RTOG) [10]. Clinical and radiological assessments were performed every 3 months for the first 2 years, every 6 months for the following 2 years, and annually thereafter. Radiographic surveillance was not routinely performed except for suspicion of disease recurrence or metastasis. Failures found on clinical or radiographic examination were classified as vaginal, loco-regional (recurrence within the pelvis including vaginal cuff), or distant (bone, lung, liver, or otherwise). Deaths were recorded for analysis.

3. Statistical Methods

The evaluated end point was overall survival (OS) using the Kaplan-Meier method, and significance was determined by the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model. Statistical analyses were performed using statistical package for social sciences (SPSS) for windows version 17 (SPSS, Chicago, IL, USA).

4. Results

The mean age was 55 years (range: 23–87 years). At the time of diagnosis, 61 patients (14.8%) were premenopausal, and 351 (85.2%) were postmenopausal. Thirty-three percent of patients were obese (mean BMI 28.97 kg/m²), and 35.2% of women had a concomitant disease (diabetes mellitus, systemic arterial hypertension, or both). Clinical and pathological characteristics of patients are described in Table 1. Three hundred fifty-nine patients (87.1%) had endomet-rioid cancer (see Table 2).

Histological grades were as follows: 165 (40%) low grade, 115 (27.9%) intermediate grade, and 130 (31.6%) high grade. Of the participants, 221 (53.6%) had myometrial (greater than half of the myometrial thickness), 57 (13.8%) had lymphovascular, 47 (11.4%) had serosal, and 38 (9.25%) had adnexial involvement. Twenty-seven patients (4.1%) had para aortic lymph node involvement, and 39 patients (9.5%)
Table 1: Characteristics of Mexican patients with endometrial carcinoma.

| Characteristics                  | Number of patients | Percentage |
|----------------------------------|--------------------|------------|
| **Age**                          |                    |            |
| <45                              | 79                 | 19.2       |
| 45–54                            | 108                | 26.2       |
| 55–64                            | 139                | 33.7       |
| 65–74                            | 61                 | 14.8       |
| ≥75                              | 25                 | 6.1        |
| **Mean age**                     | 55.19 (23–87)      |            |
| **Menopausal status**            |                    |            |
| Premenopausal                    | 61                 | 14.8       |
| Postmenopausal                   | 351                | 85.2       |
| **Body mass index (BMI)**        |                    |            |
| <30 (kg/m²)                      | 229                | 55.6       |
| >30 (kg/m²)                      | 136                | 33         |
| Not registered                   | 47                 | 11.4       |
| **Mean BMI**                     | 28.97 (12.32–48.8) |            |
| **Parity status**                |                    |            |
| Nullipara                        | 121                | 29.4       |
| Multipara                        | 291                | 70.6       |
| **Blood glucose**                |                    |            |
| <100 mg/dL                       | 309                | 75.0       |
| 100–199 mg/dL                    | 83                 | 20.1       |
| >200 mg/dL                       | 20                 | 4.9        |
| **Comorbid conditions**          |                    |            |
| Yes                              | 145                | 35.19      |
| No                               | 267                | 64.81      |
| Diabetes mellitus (DM)           | 94/412             | 22.81      |
| Systemic arterial hypertension   | 80/412             | 19.41      |
| (SAH)                            | 34/412             | 8.25       |
| Other comorbidities              | 5/412              | 1.21       |

NOS: not otherwise specified.

had pelvic lymph node involvement. FIGO stages were as follows: 221 patients (53.7%) stage I, 86 patients (20.9%) stage II, and 103 patients (24.9%) stage III, and 2 patients (0.5%) stage IVA. In Table 2, pathology characteristics of the 412 patients with endometrial carcinoma are described.

From these women, 211 (51.2%) were classified as high-risk recurrence group. Table 3 describes the frequency of histological grade according each stage of disease.

After systematic evaluation, 120 patients were treated with TAH-BSO, 20 patients with TAH-BSO-pelvic LND, and 271 patients with TAH-BSO-Pelvic/para aortic LND and omentum biopsy. Histopathological and immunohistochemical assessments were performed in all cases. The staging was based on FIGO 1988 surgical staging system. A total of 270 women received adjuvant radiotherapy, EBRT alone was administered to 11 patients, 8 patients were administered whole abdominal and pelvic EBRT plus VBT, 241 patients received EBRT + VBT, 7 patients were administered only

Table 2: Pathology characteristics for Mexican patients with endometrial carcinoma.

| Characteristic                  | Patients | Percentage |
|--------------------------------|----------|------------|
| **Stage FIGO 1988**            |          |            |
| IA                             | 46       | 11.2       |
| IB                             | 96       | 23.3       |
| IC                             | 79       | 19.2       |
| IIA                            | 44       | 10.7       |
| IIIB                           | 42       | 10.2       |
| IIIA                           | 47       | 11.4       |
| IIIB                           | 1        | .2         |
| IIIC                           | 55       | 13.3       |
| IVA                            | 2        | .5         |
| **Grade**                      |          |            |
| 1                              | 165      | 40         |
| 2                              | 115      | 27.9       |
| 3                              | 130      | 31.6       |
| NOS                            | 2        | 0.5        |
| **Lymphovascular invasion**    |          |            |
| Yes                            | 57       | 13.8       |
| No                             | 341      | 82.8       |
| NOS                            | 14       | 3.4        |
| **Number of nodes**            |          |            |
| None                           | 168      | 40.8       |
| 1–10                           | 181      | 43.9       |
| 11–20                          | 51       | 12.4       |
| 21–30                          | 4        | 1.0        |
| 31–40                          | 8        | 1.9        |
| Mean of nodes obtained at surgery | 5 (1–40) | 4.78 (0.3–20.5) |
| **Histology**                  |          |            |
| Endometrioid                    | 359      | 87.1       |
| Papillary serous                | 21       | 5.1        |
| Clear cell                      | 10       | 2.4        |
| Adenosquamous                   | 21       | 5.1        |
| Glassy cell                     | 1        | .2         |
| **Size**                       |          |            |
| <3 cm                           | 66       | 16.0       |
| 3–5.9 cm                        | 100      | 24.3       |
| >6 cm                           | 77       | 18.7       |
| NOS                             | 169      | 41.0       |
| **Isthmus invasion**           |          |            |
| Present                         | 76       | 18.4       |
| Absent                          | 336      | 81.6       |
| **Uterine cervix involvement** |          |            |
| Endocervical gland              | 52       | 12.6       |
| Stromal                         | 94       | 22.8       |
| None                            | 266      | 64.6       |
| **Serous Involvement**         |          |            |
| Present                         | 47       | 11.4       |
| Absent                          | 365      | 88.6       |
| **Positive peritoneal washing**|          |            |
| Present                         | 16       | 3.9        |
| Absent                          | 352      | 85.4       |
| NOS                             | 44       | 10.7       |
| **Adnexial involvement**       |          |            |
| Present                         | 38       | 9.2        |
| Absent                          | 374      | 90.8       |
| **Number of positive nodes**   |          |            |
| 1                              | 19/412   | 4.6        |
| 2                              | 9/412    | 2.2        |
VBT and 7 patients received EBRT to retroperitoneum and pelvis besides VBT. External beam radiotherapy was given with cobalt units and 6 MV and 15 MV linear accelerators. After surgery, radiotherapy started in a mean time of 84 days, and although available literature states starting adjuvant RT within first 6 weeks or after complete healing occurs, it is difficult to reach these policies at our institute because of the high demand of patients requiring radiotherapy and poor availability of linear accelerators. Sixty-three percent of patients had mild acute symptoms related to treatment, they were prescribed pharmacologic management with no interruptions because of severe adverse effects. Seventeen percent of patients experienced chronic symptoms, grade 2 radiation proctitis (RTOG) was the most common side effect. There were no women with acute grade 3-4 or late 3-4 gastrointestinal or genitourinary side effects. Adjuvant chemotheraphy or hormone therapy used in patients was found to have adverse pathological factors such as affected nodes or positive peritoneal washings (see Table 4).

Recurrences occurred in the first 2 years at a rate of 18% (7–63 months). Vaginal recurrence was reported in 15 patients, pelvic recurrence developed in 9, and distant metastasis in 27 patients being lung and liver the most common sites of recurrence. All patients with local or distant recurrence received systemic chemotherapy. After an average followup of 49 months, 338 patients (82%) were disease-free, and 13 (3.2%) were still alive with endometrial carcinoma. By the time this analysis was done, 85 patients were death (21%). Overall survival rate was 95% at 2 years, 84% at 5 years, and 79% at 10 years (Figure 1).

Univariate and multivariate analyses showed that age, histological grade, serosal and adnexial involvement were significantly associated with overall survival ($P = 0.0003$, $P = 0.0004$, $P = 0.005$, and $P = 0.005$, resp.) (Table 5).

5. Discussion

Endometrial cancer is one of the most common gynecologic malignancies in Mexican women, and the most common in the United States. In 2010, it was estimated that 43,470 women were diagnosed with endometrial cancer (6% of new cancer cases), and 7950 women will die of the disease. The vast majority of women will fortunately survive their disease and be rendered cured given that approximately 75% of the patients are diagnosed with early-stage disease [11]. Usually the median age at diagnosis is 62 years [4, 5] and the majority of patients being postmenopausal, likewise, in the present study, the mean age of the subjects was 55 years, and 85% were postmenopausal. Hypertension, cardiac disease, and/or diabetes mellitus were present in 35% of the patients at the time of diagnosis.

The current treatment for endometrial carcinoma involves the use of surgery, radiation therapy, hormone therapy, and chemotherapy, either alone or sequentially. Definitive diagnosis requires histopathological examination, and staging is based on FIGO surgical staging system [12]. Surgery is the mainstay treatment for most patients with endometrial cancer. In a small subset of patients who present with unresectable disease or those whose disease is resectable but medically inoperable, definitive radiation is used instead as the primary treatment. The surgical management of endometrial cancer often involves simple hysterectomy and BSO with or without lymph node staging. However, pelvic
and para aortic lymph nodal sampling and dissection has become a routine around the world, especially for patients operated by gynecologic oncologists [13–15], although this ultimate proceeding is controversial, two recent trials did not show improvement in disease-free or overall survival after lymphadenectomy in early-stage disease [16, 17]. Whether the procedure is being performed by a gynecologist or a gynecologic oncologist, the patient's general condition, the habitus of the patient, and several other factors affect the thoroughness of the lymphadenectomy. The minimum number of lymph nodes that need to be retrieved for the dissection to be representative has yet to be determined, and the final evaluation of a lymphadenectomy specimen will also depend on how meticulously the specimens are examined by the pathologist. Also, pelvic lymph nodal involvement is likely a marker for a biologically aggressive disease with a propensity for distant failures; any pelvic radiation offered in that setting is aimed at essentially improving local-regional control. However, the concern has been raised that omitting lymphadenectomy in patients with grade 1 tumors may lead to inappropriate postoperative treatment [18]. With regard to the type of surgery in our study 120 patients were treated with TAH-BSO, 20 patients with TAH-BSO-pelvic LND, and 271 patients with TAH-BSO-Pelvic/para-aortic LND and peritoneal washings and omentum biopsy.

Approximately 70–80% of patients with endometrial cancer are diagnosed at stage I with a favorable prognosis [17, 19, 20]. Because the concept of stage grouping is based on creating groups with similar prognoses, it is not surprising that the outcome gets less favorable with advancing stage. Reported results of stage-based survival are remarkably consistent, with stages I, II, III, and IV disease having 5-year survival rates of 92%, 80%, 40%, and 5%, respectively [21]. In the present study, 221 (53.7%) of the patients had stage I disease at the time of diagnosis, while 86 patients (20.9%) had stage II, and 103 patients (24.9%) had stage III disease, and 2 patients (0.5%) had stage IV A disease.

The low-risk group includes patients with stage IA G1, G2 tumors. The risk of pelvic lymph nodal positivity [22] is less than or equal to 3%, and the 5-year progression-free survival rate in this group is on the order of 90% to 96%. It is unlikely that postoperative pelvic external-beam radiation would add anything to the final outcome, and therefore radiation is not routinely recommended to this group of patients [23–26]. The role of intravaginal radiation in these patients is also of questionable benefit because of a very low rate of vaginal recurrence with surgery alone. These patients have the lowest risk of recurrence [27]. This was verified by the findings of prospective studies conducted between 1977 and 1983 by the Gynecologic Oncology Group (GOG 33), which investigated the patterns of failure for early-stage disease [22]. Of the women who had no myometrial invasion with grade 1 or 2 histology, none experienced recurrence [23]. In addition, a Cochrane review of the treatment for stage I endometrial cancer found a statistically significant greater risk for death in patients who had EBRT versus no treatment with low risk factors (i.e., disease confined to the endometrium, <50% myometrial invasion or grade 1/2) [17]. These data were confirmed again by meta-analysis of seven randomized trials by Johnson and Cornes showing that prophylactic EBRT could be harmful or ineffective in improving survival in women with low- or intermediate-risk cancer [19].

The intermediate-risk group has been defined by the GOG as those with pathologic stage IB to IIB (occult cervical involvement). It is in this risk category in which most of the controversy resides about the indication and type of radiation needed. With regard to the indication of adjuvant radiation in intermediate-risk patients, the controversy relates to the lack of improvement in overall survival with the use of adjuvant radiation compared with surgery alone. The two recently completed randomized trials demonstrating lack of survival advantage leads to the conclusion that adjuvant radiation is not needed. The policies for the use of radiotherapy have changed compared with trials, where EBRT + VBT were obligated for every patient operated with endometrial carcinoma [13, 14]. With more common use of lymphadenectomy during surgery, the value of adjuvant pelvic RT given to lymph-node negative areas has become questioned, and now patients from the intermediate risk group seem to benefit only from adjuvant VBT [15, 16, 28]. The inclusion criteria for this group vary slightly from trial to trial. These risk factors include, age, lymphovascular space invasion, tumor size, cervical involvement, and deep
Table 4: Treatment characteristics of Mexican patients with endometrial carcinoma.

| Characteristic                                      | Patients | Percentage |
|-----------------------------------------------------|----------|------------|
| **Surgery**                                         |          |            |
| TAH-BSO                                             | 120      | 29.1       |
| TAH-BSO-pelvic LND                                  | 20       | 4.9        |
| TAH-BSO-Pelvic/para aortic LND and omentum biopsy   | 271      | 65.8       |
| Pelvic exenteration                                 | 1        | 0.2        |
| **Lymph node dissection**                           |          |            |
| Pelvic                                              | 296/412  | 71.8       |
| Para aortic                                         | 273/412  | 66.3       |
| **Chemotherapy**                                    |          |            |
| Yes                                                 | 59       | 14.3       |
| No                                                  | 353      | 85.7       |
| Concurrent with RT                                  | 25/59    | 6.1        |
| Sequential chemotherapy                             | 31/59    | 7.5        |
| Adjuvant without RT                                 | 3/59     | 0.7        |
| **Chemotherapy agents used**                        |          |            |
| Cisplatin/adriamicin                                | 15       | 3.6        |
| Cisplatin                                           | 2        | 0.5        |
| CisCA regimen                                       | 4        | 1.0        |
| Carboplatin/adriamicin/ciclophosphamide             | 1        | 0.2        |
| PVC regimen                                         | 3        | 0.7        |
| Adriamicin                                          | 3        | 0.7        |
| Cisplatin/adriamicin/ciclophosphamide               | 1        | 0.2        |
| Ciclophosphamide/adriamic                          | 1        | 0.2        |
| Cisplatin/paclitaxel                                | 2        | 0.5        |
| Carboplatin                                         | 22       | 5.3        |
| Carboplatin/paclitaxel                              | 4        | 1.0        |
| Gemcitabine                                         | 1        | 0.2        |
| **Hormone therapy**                                 |          |            |
| Yes                                                 | 10       | 2.4        |
| No                                                  | 402      | 97.6       |
| **Radiotherapy**                                    |          |            |
| Yes                                                 | 270      | 65.53      |
| No                                                  | 142      | 34.47      |
| Pelvic EBRT                                         | 11/270   | 4.08       |
| WART + pelvic RT + VBT                             | 8/270    | 2.96       |
| EBRT + VBT                                         | 241/270  | 89.26      |
| VBT                                                | 7/270    | 2.59       |
| Pelvic + retroperitoneum EBRT + VBT                | 3/270    | 1.11       |
| **Brachytherapy**                                   |          |            |
| Yes                                                 | 255/412  | 61.89      |
| No                                                  | 157/412  | 38.11      |
| High-dose rate                                      | 14/255   | 5.49       |
| Low-dose rate                                       | 241/255  | 94.51      |

TAH-BSO: total abdominal hysterectomy, TAH-BSO-LND: total abdominal hysterectomy and lymph node dissection, EBRT: external beam radiotherapy, WART: whole abdominal radiotherapy, and VBT: vaginal vault brachytherapy.
Table 5: Multivariate analysis using cox regression model for prognostic factors for overall survival in patients with endometrial carcinoma.

| Characteristic       | HR   | IC 95%       | P   |
|----------------------|------|--------------|-----|
| Grade                |      |              |     |
| 1                    | 1.00 |              |     |
| 2                    | 3.40 | 1.62–7.09    | 0.004|
| 3                    | 4.97 | 2.44–10.10   |     |
| Serosal involvement  |      |              |     |
| Yes                  | 2.51 | 1.44–4.38    | 0.005|
| No                   | 1.00 |              |     |
| Adnexial involvement |      |              |     |
| Yes                  | 2.31 | 1.25–4.30    | 0.005|
| No                   | 1.00 |              |     |
| Age (years)          |      |              |     |
| <45                  | 1.00 |              |     |
| 45–54                | 0.66 | 0.30–1.44    |     |
| 55–64                | 0.97 | 0.50–1.89    | 0.003|
| 65–74                | 1.33 | 0.63–2.82    |     |
| >75                  | 5.40 | 2.44–11.93   |     |

myometrial invasion. Despite multiple randomized studies, this group is still the most controversial with regard to adjuvant radiotherapy because it is not clear whether the benefit of treatment outweighs the risks. In a trial conducted by Aalders et al., all patients received vaginal brachytherapy and then were randomized to no further treatment or EBRT. There was a significant reduction in pelvic and vaginal recurrences in patients who received EBRT although these patients had more distant metastases. The 5-year overall survival (OS) was not improved by EBRT, although a more detailed analysis of the series concluded that patients with higher risk factors such as poorly differentiated tumors (grade 3), who have greater than 50% myometrial invasion might benefit from EBRT [29].

The Postoperative Radiation in Endometrial Cancer (PORTEC 1) trial in which 714 patients with stage IB G2,3 and IC G1,2 were randomized after TAH-BSO and without lymph nodal sampling to observation (N = 360) or pelvic radiation (N = 354) to a total dose of 46 Gy in 23 fractions. With a median followup of 52 months, the 5-year locoregional control was 96% in the radiation arm compared with 86% in the observation arm (P < 0.001). The corresponding 5-year survival rates were 81% and 85%, respectively (P = 0.37) [16]. Recently a PORTEC 15 year actualization confirmed the highly significant improvement of local control obtained by EBRT but an absence of survival benefit. Besides, a trend to develop second primary cancers was found over 15 years in 19% of all patients, 22% versus 16% for EBRT versus no additional treatment (P = 0.10), with observed versus expected ratios of 1.6 (EBRT) and 1.2 (no additional treatment) compared with a matched population (P = NS) [30]. Of the randomized studies, the GOG 99 study was the only study that required FIGO surgical staging. Three hundred ninety-two patients with stage IB to IIB endometrial cancer who underwent TAH-BSO and pelvic and para aortic lymph nodal sampling were randomized to observation (N = 202) or postoperative pelvic radiation (N = 190) to a total dose of 50.4 Gy in 28 fractions. The study was designed to have an 80% chance of detecting a 58% decrease in the recurrence hazard rate and a 56% decrease in death hazard rate. The primary outcome was recurrence-free interval and is defined as the time from study entry to clinical, histologic, or radiographic evidence of disease recurrence. With a median followup of 69 months, the 2-year cumulative incidence of recurrence was 12% in the observation group and 3% in the adjuvant radiotherapy group. This was statistically significant (P = 0.007). The estimated 4-year survival rate was 86% in the observation group, compared with 92% in the irradiated group. This was not a statistically significant difference (P = 0.557) [31]. A recurrence rate of 12–14% was reported in patients treated with surgery alone in PORTEC and GOG-99 trials, with isolated vaginal recurrence as the most common form of recurrent disease [16, 31]. With regard to side effects, a complication rate of 25% and 15%, respectively, was reported for patients receiving pelvic RT in these two trials. The complication rate associated with the pelvic irradiation in the GOG-99 study was much higher than that in the PORTEC study, probably because of the extent of surgical staging. The rate of severe (grade 3 or 4) gastrointestinal toxicity with radiation were 8% in the GOG study but only 3% in the PORTEC trial. In our study, 17% of the patients had RTOG grade 1-2 late side effects mainly gastrointestinal effects, with 3 patients having grade 3-4 side effects.

The ASTEC-EN5 trial, which is a pooled meta-analysis of two randomized trials (ASTEC and EN.5), was designed to evaluate the benefit of postoperative adjuvant EBRT in women with intermediate- and high-risk early-stage endometrial cancer. Between 1996 and 2005, 905 patients with intermediate-risk or high-risk endometrial cancer were randomly assigned to observation or external-beam radiotherapy. Vaginal brachytherapy was allowed based on each center’s policy. As a result, 51% of the observation group received vaginal brachytherapy. Not surprisingly, the analysis did not find any evidence of overall survival benefit with external-beam radiotherapy [32].

The only trial comparing VBT versus RT is the second study in the PORTEC series. This noninferiority multicenter trial randomized patients with a high intermediate risk of recurrence defined as age 60 years and above and stage IC grades 1 or 2 or stage IB grade 3, and any age with stage IIA grades 1, 2 or grade 3 with less than 50% invasion. A total of 427 patients were recruited to this trial between 2002 and 2006, with a median follow-up time of 45 months. There was no significant difference in OS and the 5-year locoregional recurrence rate between treatment modalities. The lack of difference in survival in PORTEC-2 raises the question of whether adjuvant therapy is needed at all for patients with intermediate-risk disease. The estimated 5-year vaginal recurrence rates were 1.8% (95% CI) after VBT and 1.6% (95% CI) after EBRT [33]. Regarding the quality of life...
for patients enrolled in this study, the EBRT group reported significant and clinically relevant higher levels of diarrhea and fecal leakage, which limited social and daily activities for the EBRT group \( (P < 0.001) \) [34].

It is well known that pelvic RT helps to reduce locoregional recurrences and mortality in patients with multiple high risk factors (myometrial invasion greater than 50%, grade 3, gross involvement of the cervix or advanced-stage disease, lymphovascular space involvement, and aggressive histologic types) but with no benefit for the risk of distant metastases. In 2004, Creutzberg and colleagues [35] reported their findings for 104 patients with stage IC, grade 3 tumors who had registered but were not included in the first PORTEC trial, comparing their survival with that of the patients included in that trial. Grade 3 tumors were found to have a much higher metastasis rate than grades 1 or 2 tumors; multivariate analysis showed that histologic grade 3 was the most important adverse prognostic factor for relapse and death from endometrial cancer. These findings raise the question of whether radiation alone is enough for grade 3 tumors or whether the better strategy may be a combination of radiation and chemotherapy. For such patients, chemotherapy (CT) has been proposed as a potentially beneficial therapeutic approach with randomized controlled trials specific to this exact subset of patients. Multiple studies have addressed which treatment might be better should they be combined, and if combined, what chemotherapy should be used. Still, the search for effective cytotoxic agents for the treatment of endometrial carcinoma continues. To date only three drugs with definite activity have been identified: doxorubicin, cisplatin, and paclitaxel [36].

Early results of a study done by the Nordic Society of Gynecologic Oncology and the European Organization for Research and Treatment of Cancer were presented at the American Society of Clinical Oncology meeting in May 2007 [37]. The NSGO-EC-9501/EORTC-55991 trial randomly assigned 382 patients between 1996 and 2007 to receive adjuvant radiation therapy \( (n = 196) \) or radiation therapy plus chemotherapy \( (n = 186) \). Patients with surgical stages I, II, IIIA (positive peritoneal fluid cytology only), or IIIC (positive pelvic lymph nodes only) disease were eligible if they were considered to be at sufficiently high risk for micrometastatic disease to qualify for adjuvant therapy. Patients with serous, clear cell, or anaplastic carcinomas were eligible regardless of risk factors. Patients with para aortic metastases were not eligible. Lymph node exploration at surgical staging was optional. All patients underwent at least a total abdominal hysterectomy with bilateral salpingo-oophorectomy. Pelvic radiation therapy, with or without vaginal brachytherapy, was given to a dose of 44 Gy. Chemotherapy was given before or after the radiation. Before August 2004, the chemotherapy regimen consisted of four courses of cisplatin and doxorubicin or epirubicin; after that time, several chemotherapy regimens were allowed. The median follow-up time was 4.3 years. The hazard ratio for progression-free survival in the study was 0.62 (95% CI, 0.40 to 0.97; \( P = 0.03 \)), which translated to an estimated difference in 5-year progression-free survival rate of 7% (from 72% for those given radiation to 79% for those given chemoradiation therapy) [37]. The corresponding findings for overall survival were similar; the hazard ratio was 0.65 (95% CI, 0.40 to 1.06; \( P = .08 \)), for an estimated difference in 5-year overall survival rate of 8% (74% for radiation versus 82% for chemoradiation therapy). The investigators concluded that even though 27% of the patients assigned to the chemoradiation therapy group received little or none of the prescribed chemotherapy, chemoradiation therapy was still better than radiation alone for patients with early endometrial cancer at high risk for micrometastasis [37]. The Japanese GOG was a randomized study that enrolled 475 patients with stages IC–IIIC endometrial carcinoma with deeper than 50% myometrial invasion (FIGO 1988 criteria). They were randomized to receive adjuvant EBRT or cyclophosphamide, doxorubicin, and cisplatin. A pelvic lymphadenectomy was performed in 96.1% of the patients and a para aortic lymphadenectomy was performed in 28.6%. The OS and PFS were not statistically different between the two arms. In their subgroup analysis of HIR patients, they found a significant benefit in PFS rate \( (P = 0.24) \) and OS rate \( (P = 0.06) \) for the chemotherapy group [38]. In the present study, 3 patients received CT alone, 25 concurrently with RT and 31 in sequential mode (CT first).

For many years, adjuvant wide-field RT+CT has been used for advanced stage patients [39, 40]. However, GOG-122 study recruiting stages III-IV patients showed a survival advantage for CT alone compared to whole-abdominal RT [39]. Eight patients in our study received whole abdominal RT and during the postoperative period, among stage III patients, three received para aortic lymph node involvement [25, 34, 41]. In our study, the significance of these factors was examined with univariate and multivariate analyses, showing statistical significance for overall survival for age, grade, and serosal and adnexal involvement \( (P = 0.05) \).

The overall survival at 2, 5, and 10 years was 95%, 84%, and 79.4%, respectively, these results are consistent with others reported in the literature [28]. After a mean followup of 49 months, 338 patients (82%) were still alive without disease, 13 (3%) were alive with disease, and 85 (21%) were dead by the time this analysis was done. Recurrences presented in the first two years after treatment in 18% of patients being vaginal and locoregional (pelvic) the most common.

6. Conclusion

This retrospective analysis of 412 women with endometrial cancer reveals statistically significant differences in pathologic disease characteristics among those with adenocarcinoma of the endometrium receiving surgery alone or surgery followed by adjuvant RT at our institution. Despite
endometrial carcinoma being one of the most common gynecologic malignancies in female tract, controversy exists regarding the role of adjuvant radiotherapy. Despite the statistically significant benefit of adjuvant RT on local control observed in the adjusted analysis, we recognize that this is a retrospective study that is prone to inherent bias. Important pathologic and clinical factors, including tumor diameter, lymphovascular space invasion, adequate lymph node evaluation, and positive peritoneal washings, were not sufficiently represented to allow for evaluation and adjustment in this series' analysis. We recognize the potential biases that these and other factors can introduce into an analysis of this kind and do not espouse these data as definitive proof of the benefit of RT in the adjuvant setting.

To our knowledge, this is the largest series exploring the characteristics of Mexican patients treated for endometrial carcinoma in the literature. We conclude that adjuvant radiotherapy should be considered an integral component of definitive treatment for women with unfavorable disease as a mean to decrease mortality and improve patient outcome. Future work is needed to delineate clinical and biologic factors that can guide treatment and account for disparities in outcomes between subsets of women with endometrial carcinoma, including patterns of care analyses and prospective studies of adjuvant radiotherapy modalities and tumor-specific treatment strategies.

Acknowledgment

The authors would like to thank A. C. de la Rosa from the Biostatistics Department of our Institution for his assistance with the statistical analysis.

References

[1] Instituto Nacional de Estadistica Geografía e Informática, Estadísticas Vitales, 1998–2008. Bases de datos, http://www.inegi.org.mx.
[2] Registro Histopatológico de Neoplasias malignas, México: Secretaría de Salud, 2003.
[3] P. Rizo, M. I. Sierra, and G. Vázquez, “Registro hospitalario de cáncer: compendio de cáncer 2000–2004,” Cancerologia, vol. 2, pp. 2203–2287, 2007.
[4] A. Jemal, R. Siegel, Ward E. Ward et al., “Cancer statistics 2011,” CA—A Cancer Journal for Clinicians, vol. 61, pp. 212–236, 2011.
[5] American College of Obstetricians and Gynecologists, “Management of endometrial cancer, ACOG Practice Bulletin No. 65,” Gynecologic Oncology, vol. 106, pp. 413–425, 2005.
[6] N. Howlader, A. M. Noone, M. Krapcho et al., Eds., “SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations),” National Cancer Institute. Bethesda, Md, USA, 2011, http://seer.cancer.gov/csr/1975_2009_pops09/.
[7] National Comprehensive Cancer Network (NCCN), 2011, http://www.nccn.org.
[8] D. G. Mutch, “The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas,” Gynecologic Oncology, vol. 115, pp. 325–328, 2009.
[9] J. D. Cox, J. Stetz, and T. F. Pajak, “Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC),” International Journal of Radiation Oncology Biology Physics, vol. 31, no. 5, pp. 1341–1346, 1995.
[10] J. I. Sorosky, “Endometrial cancer,” Obstetrics and Gynecology, vol. 111, no. 436, p. 447, 2008.
[11] F. L. Greene, D. L. Page, I. D. Fleming, and A. Fritz, The AJCC Cancer Staging Manual, Springer, New York, NY, USA, 6th edition, 2002.
[12] T. Onda, H. Yoshikawa, K. Mizutani et al., “Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy,” British Journal of Cancer, vol. 75, no. 12, pp. 1836–1841, 1997.
[13] B. W. Corn, R. M. Lancia, K. M. Greven et al., “Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis,” Journal of Clinical Oncology, vol. 12, no. 3, pp. 510–515, 1994.
[14] D. S. Mohan, M. A. Samuels, M. A. Selim et al., “Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma,” Gynecologic Oncology, vol. 70, no. 2, pp. 165–171, 1998.
[15] C. L. Creutzberg, W. L. van Putten, and P. C. Koper, “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation Therapy in endometrial carcinoma,” The Lancet, vol. 355, no. 9213, pp. 1404–1411, 2000.
[16] A. N. Scholten, W. L. van Putten, H. Beerman et al., “Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 3, pp. 834–838, 2005.
[17] A. Kong, I. Simera, M. Collingwood, C. Williams, H. Kitchener, and Cochrane Gynecological Cancer Group, “Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis,” Annals of Oncology, vol. 18, no. 10, pp. 1595–1604, 2007.
[18] I. Ben-Shachar, J. Pavelka, D. E. Cohn et al., “Surgical staging for patients presenting with grade 1 endometrial carcinoma,” Obstetrics and Gynecology, vol. 105, no. 3, pp. 487–493, 2005.
[19] N. Johnson and P. Cornes, “Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 114, no. 11, pp. 1313–1320, 2007.
[20] C. M. Lee, A. Szabo, D. C. Shrieve, O. K. Macdonald, and D. K. Gaffney, “Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma,” Journal of the American Medical Association, vol. 295, no. 4, pp. 389–397, 2006.
[21] D. Nori, B. S. Hilaris, M. A. Batata et al., “Clinical application of remote afterloaders with special reference to endometrial cancer,” in Brachytherapy Oncology, Memorial Hospital Annual Brachytherapy Proceedings, pp. 101–118, MSKCC Publishers, New York, NY, USA, 1983.
[22] W. T. Creasman, C. P. Morrow, B. N. Bundy, H. D. Honesley, J. E. Graham, and P. B. Heller, “Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study,” Cancer, vol. 60, no. 8, pp. 2035–2041, 1987.
[23] C. P. Morrow, B. N. Bundy, R. J. Kurman et al., “Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 40, no. 1, pp. 55–65, 1991.
10

[24] M. Carey and G. O’Connell, “Good outcome associated with a standardized treatment protocol using selective postoperative radiation with clinical stage I adenocarcinoma of the endometrium,” Gynecologic Oncology, vol. 57, no. 2, pp. 138–144, 1995.

[25] H. Kucera, N. Vaura, and K. Weghoupt, “Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors,” Gynecologic Oncology, vol. 38, no. 1, pp. 99–104, 1990.

[26] P. Elliott, D. Green, A. Coates et al., “The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer,” International Journal of Gynecological Cancer, vol. 4, no. 2, pp. 84–93, 1994.

[27] S. B. Dewdney and D. G. Mutch, “Evidence-based review of the utility of radiation therapy in the treatment of endometrial cancer,” Women’s Health, vol. 6, no. 5, pp. 695–704, 2010.

[28] A. F. Korcum, E. Duman, and G. Aksu, “The results of adjuvant radiotherapy in endometrial carcinoma,” Gynecological Endocrinology, vol. 26, no. 4, pp. 240–245, 2010.

[29] J. Aalders, V. Abeler, P. Kolstad, and M. Onsrud, “Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients,” Obstetrics and Gynecology, vol. 56, no. 4, pp. 419–427, 1980.

[30] C. L. Creutzberg, R. A. Nout, M. L. M. Lybeert et al., “Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 4, pp. e631–e638, 2011.

[31] H. M. Keys, J. A. Roberts, V. L. Brunetto et al., “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 92, no. 3, pp. 744–751, 2004.

[32] ASTEC/EN.5 Study Group, “Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis,” The Lancet, vol. 373, no. 9658, pp. 137–146, 2009.

[33] R. A. Nout, V. T. H. B. M. Smit, H. Putter et al., “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial,” The Lancet, vol. 375, no. 9717, pp. 816–823, 2010.

[34] R. A. Nout, H. Putter, I. M. Jurgenliemk-Schulz et al., “Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3547–3556, 2009.

[35] C. L. Creutzberg, W. L. van Putten, C. C. Warlaim-Rodenhiis et al., “Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1234–1241, 2004.

[36] D. S. Miller, J. A. Blessing, R. D. Drake et al., “A phase II evaluation of pemetrexed (Alimta, LY31514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group,” Gynecologic Oncology, vol. 115, pp. 443–446, 2009.

[37] T. Hogberg, P. Rosenberg, G. Kristensen et al., “A randomized phase III study on adjuvant treatment with radiation ± chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991),” Journal of Clinical Oncology, vol. 25, supplement 18, Article ID S5503, 2007, ASCO Annual Meeting Proceedings.

[38] N. Susumu, S. Sage, and Y. Udagawa, “Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 108, no. 1, pp. 226–233, 2008.

[39] M. E. Randall, V. L. Filiaci, H. Muss et al., “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 36–44, 2006.

[40] D. A. Fishman, K. B. Roberts, J. T. Chambers, E. I. Kohorn, P. E. Schwartz, and S. K. Chambers, “Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium,” Gynecologic Oncology, vol. 61, no. 2, pp. 189–196, 1996.

[41] W. T. Creasman, F. Odidino, P. Maisonneuve et al., “Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer,” International Journal of Gynecology and Obstetrics, vol. 95, supplement 1, pp. S105–S143, 2006.